A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best oversold NASDAQ stocks to buy now. On June 30, H.C. Wainwright ...

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs), according to a study published online July 9 in ...

People who use GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, or GERD, a new ...

Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) ...

In this cohort study, the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) semaglutide and tirzepatide was associated with ...

Men were three times more likely than women to say GLP-1s boosted their confidence and two times more likely to say they were going on more dates. They also reported higher libido, more matches and ...

New Phase II data presented at ENDO 2025 highlight avexitide’s potential to significantly reduce severe hypoglycemic events ...

Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

Innovent Biologics, the first Chinese company to win regulatory approval to sell a GLP-1 drug for weight loss and diabetes, ...

Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared ...

Recently, research results have been announced that GLP-1 (glucagon-like peptide) receptor agonist drugs have a positive ...